- Market Capitalization, $K 7,994
- Shares Outstanding, K 3,736
- Annual Sales, $ 1,670 K
- Annual Income, $ -15,190 K
- 60-Month Beta 1.79
- Price/Sales 4.92
- Price/Cash Flow N/A
- Price/Book 3.68
|Period||Period Low||Period High||Performance|
| || |
-0.58 (-23.20%)since 10/11/19
| || |
-1.10 (-36.42%)since 08/12/19
| || |
-7.38 (-79.35%)since 11/12/18
Capricor (CAPR) delivered earnings and revenue surprises of 38.57% and -35.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
BEVERLY HILLS, Calif. (AP) _ Capricor Therapeutics Inc. (CAPR) on Thursday reported a loss of $1.6 million in its third quarter.
Provides Update on End of Phase Type-B Meeting with FDA
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other...
Call Scheduled for Thursday, October 24 at 10:30am Eastern Time
CHF Solutions' (CHFS) Aquadex system to be used for the outpatient study on heart failure, conducted by James A. Haley Veterans' Hospital and Clinics. The study receives final approval.
--Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies--
Zynex (ZYXI) is likely to maintain the current high on a number of favorable factors.
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD)...
Abbott (ABT) is upbeat about the latest clearance in its neuromodulation product portfolio.
The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.
Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.
The market is approaching oversold territory. Be watchful of a trend reversal.